XML 106 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1

Notes to the consolidated financial statements - Additional Information (Details) € in Thousands, $ in Millions	1 Months Ended		12 Months Ended
	Jul. 31, 2020 EUR (€) item	Aug. 31, 2014 EUR (€)	Dec. 31, 2023 EUR (€) item	Dec. 31, 2022 EUR (€) item	Dec. 31, 2021 EUR (€)	Apr. 30, 2021 EUR (€)	Dec. 31, 2019 USD ($)	Nov. 30, 2017 USD ($)
Notes to the Consolidated Statements of Operations
Revenue recognized			€ 53,758	€ 67,420	€ 102,990
Proceeds from issuing shares			€ 235,840		404,062
Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding | item			2	2
Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets | item			2	1
Research And Development Services Combined With Ip License Member
Notes to the Consolidated Statements of Operations
Revenue recognized			€ 31,051	€ 44,787	79,827
Product
Notes to the Consolidated Statements of Operations
Revenue recognized			11,395	19,571	22,706
Research and development services
Notes to the Consolidated Statements of Operations
Revenue recognized			11,312	3,062	457
Boehringer Ingelheim
Notes to the Consolidated Statements of Operations
Revenue recognized			0	0	26,003
Upfront Payments Received Or Receivable		€ 30,000
Option Fee payment		5,000
Additional development milestone payments		€ 7,000
Upfront Payment Revenue Recognized From Termination Of Agreement			14,003
Ifrs Option Fee Payment Included In Contract Liabilities			5,000
Development milestone payment included in contract liabilities			7,000
CRISPR Therapeutics
Notes to the Consolidated Statements of Operations
Revenue recognized			5,425	3,370	919
Upfront Payments Received Or Receivable | $								$ 3
Genmab | Collaboration and License Agreement
Notes to the Consolidated Statements of Operations
Revenue recognized			1,197	1,787	1,770
Upfront Payments Received Or Receivable | $							$ 10
Equity investment | $							$ 20
GSK [Member] | Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines
Notes to the Consolidated Statements of Operations
Revenue recognized			27,740	41,379
GSK [Member] | GlaxoSmithKline COVID Agreement
Notes to the Consolidated Statements of Operations
Revenue recognized			10,530	20,884
Upfront Payments Received Or Receivable						€ 75,000
GSK [Member]
Notes to the Consolidated Statements of Operations
Proceeds from issuing shares	€ 150,000
Upfront Payments Received Or Receivable	120,000		220,000
Amount Eligible To Receive As One Time Reimbursable Payment For Manufacturing Capacity Reservation	30,000
Amount Eligible To Receive As Development And Regulatory Milestone Payments	320,000
Amount Eligible To Receive As Commercial Milestone Payments	€ 380,000
Number of performance obligations | item	2
GSK [Member] | Belgium
Notes to the Consolidated Statements of Operations
Revenue recognized			€ 47,128	€ 62,263	€ 74,298

X

- Definition

The amount of additional development milestone payment received.

+ References

No definition available.

+ Details

Name:	cvac_AdditionalDevelopmentMilestonePaymentsReceived
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount eligible to receive commercial milestone payments.

+ References

No definition available.

+ Details

Name:	cvac_AmountEligibleToReceiveAsCommercialMilestonePayments
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount eligible to receive development and regulatory milestone payments.

+ References

No definition available.

+ Details

Name:	cvac_AmountEligibleToReceiveAsDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount eligible to receive as a one-time reimbursable payment for manufacturing capacity reservation upon completion.

+ References

No definition available.

+ Details

Name:	cvac_AmountEligibleToReceiveAsOneTimeReimbursablePaymentForManufacturingCapacityReservation
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The amount of development milestone payment included in contract liabilities

+ References

No definition available.

+ Details

Name:	cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

The amount of Option fee payment included in contract liabilities

+ References

No definition available.

+ Details

Name:	cvac_IfrsOptionFeePaymentIncludedInContractLiabilities
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Number of collaboration partners that owed 100% of all the receivables and contract assets outstanding of the company.

+ References

No definition available.

+ Details

Name:	cvac_NumberOfCollaborationPartnersThatOwedHundredPercentOfAllReceivablesAndContractAssetsOutstanding
Namespace Prefix:	cvac_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of collaboration partners with balances greater than 10% of the total amounts of receivable and contract assets.

+ References

No definition available.

+ Details

Name:	cvac_NumberOfCollaborationPartnersWithBalancesGreaterThanTenPercentOfAllReceivablesAndContractAssets
Namespace Prefix:	cvac_
Data Type:	xbrli:decimalItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Represents the number of performance obligations.

+ References

No definition available.

+ Details

Name:	cvac_NumberOfPerformanceObligations
Namespace Prefix:	cvac_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of Option fee Payment received.

+ References

No definition available.

+ Details

Name:	cvac_OptionFeePayment
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of upfront payment revenue recognized from termination of agreement.

+ References

No definition available.

+ Details

Name:	cvac_UpfrontPaymentRevenueRecognizedFromTerminationOfAgreement
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of upfront payments received or receivable by the company.

+ References

No definition available.

+ Details

Name:	cvac_UpfrontPaymentsReceivedOrReceivable
Namespace Prefix:	cvac_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2023-01-01
-Paragraph 24
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2023-01-01
-Paragraph B16
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B16&doctype=Appendix&subtype=B
-URIDate 2023-03-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2023-01-01
-Paragraph 54
-Subparagraph e
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_e&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_InvestmentAccountedForUsingEquityMethod
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

The cash inflow from issuing shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 7
-IssueDate 2023-01-01
-Paragraph 17
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_ProceedsFromIssuingShares
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ordinary activities in exchange for consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2023-01-01
-Paragraph 114
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard
-URIDate 2023-03-23

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 15
-IssueDate 2023-01-01
-Paragraph 113
-Subparagraph a
-URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard
-URIDate 2023-03-23

+ Details

Name:	ifrs-full_RevenueFromContractsWithCustomers
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesCombinedWithIpLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cvac_BoehringerIngelheimMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cvac_CrisprTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cvac_GenmabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	cvac_IfrsTypeOfArrangementAxis=cvac_CollaborationAndLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	cvac_IfrsTypeOfArrangementAxis=cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	cvac_IfrsTypeOfArrangementAxis=cvac_GlaxosmithklineCovidAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	ifrs-full_GeographicalAreasAxis=country_BE
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: